R&D

R&D
GEXVal Receives Funding from a Parkinson’s Research Program at The Michael J. Fox Foundation
2025/2/14

GEXVal Inc.February 14, 2025 GEXVal Inc. (President & CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, […]

Read more
R&D
GEXVal Selected for AMED’s ‘Strengthening Program for Pharmaceutical Startup Ecosystem’
2024/12/16

GEXVal Inc.16 December, 2024 We are delighted to announce that GEXVal Inc.'s planned global Phase 2a Proof of […]

Read more
R&D
GEXVal Completes Phase I Clinical Trial of GXV-001 in Australia
2024/7/1

GEXVal Inc.July 1, 2024 GEXVal Completes Phase I Clinical Trial of GXV-001 in Australia We are pleased to anno […]

Read more
R&D
GEXVal Sponsors SLTBR 2024 35th Annual Meeting
2024/6/18

GEXVal Inc.June 18, 2024 GEXVal Sponsors SLTBR 2024 35th Annual Meeting GEXVal Inc. is proud to sponsor the 35 […]

Read more
R&D
GEXVal Inc. Announces Collaboration with FRAXA-DVI
2023/2/28

GEXVal Inc.February 28, 2023 GEXVal Inc. is pleased to announce that we have initiated a collaboration project […]

Read more